Brain Cancer Clinical Trials in Boston

Showing 61-80 of 190 trials

VB-111 in Surgically Accessible Recurrent/Progressive GBM

NCT04406272

This research study is studying a new viral cancer therapy, ofranergene obadenovec (VB-111), for recurrent or progressive glioblastoma (GBM), a brain tumor that is growing or progressing despite earlier treatment.

GlioblastomaRecurrent Glioblastoma

Dana-Farber Cancer Institute15 participantsStarted Aug 2020

Los Angeles, California, United States • Boston, Massachusetts, United States • San Antonio, Texas, United States +1 more locations

TERMINATEDPhase 2< 1 mile

Study of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab in Subjects With Recurrent or Progressive Glioblastoma

NCT04006119

This research study involves an investigational product: Ad-RTS-hIL-12 given with veledimex for production of human IL-12. IL-12 is a protein that can improve the body's natural response to disease by enhancing the ability of the immune system to kill tumor cells and may interfere with blood flow to the tumor. Cemiplimab-rwlc (Libtayo) is an antibody (a kind of human protein) that is being tested to see if it will allow the body's immune system to work against glioblastoma tumors. Libtayo (cemiplimab-rwlc) is currently FDA approved in the United States for metastatic cutaneous cell carcinoma (CSCC), but is not approved in glioblastoma. Cemiplimab-rwlc may help your immune system detect and attack cancer cells. Ad-RTS-hIL-12 and veledimex will be given in combination with cemiplimab-rwlc to enhance the IL-12 mediated effect observed to date. The main purpose of this study is to evaluate the safety and efficacy of a single tumoral injection of Ad-RTS-hIL-12 given with oral veledimex in combination with cemiplimab-rwlc.

Glioblastoma

Alaunos Therapeutics40 participantsStarted Aug 2019

Los Angeles, California, United States • San Francisco, California, United States • Jacksonville, Florida, United States +4 more locations

VB-111 in Surgically Accessible Recurrent/Progressive GBM

Study of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab in Subjects With Recurrent or Progressive Glioblastoma

Brain Cancer Trials in Other Cities

A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Glioblastoma or Malignant Glioma

REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma

Safety, Pharmacokinetics and Efficacy of Paxalisib (GDC-0084) in Newly-diagnosed Glioblastoma

MCT for the Harvard/UCSF ROBIN Center

Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)

Feasibility of the LUM Imaging System for Detection of Cancer to the Brain

Adavosertib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma

Oral ONC201 in Adult Recurrent Glioblastoma

Psychological Intervention For Brain Tumor Caregivers

Brain Tumor Intraoperative Ultrasound Database

Psychological Intervention for Caregivers of Patients With Malignant Gliomas

Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma

Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma

Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)

Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors

A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma

Oral AMXT 1501 Dicaprate in Combination With IV DFMO

Other Conditions in Boston